Home  /  Resource Library  /  Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Results of a phase II study investigating Nivolumab for treatment of relapsed follicular lymphoma. (Abstract only)